What oral NSAID options can be taken once daily?

Once-Daily Oral NSAID Options

The primary once-daily oral NSAIDs available are meloxicam (7.5-15 mg), nabumetone (1000-2000 mg), piroxicam (10-20 mg), and oxaprozin (600-1200 mg), with meloxicam being the most commonly prescribed due to its favorable dosing profile and COX-2 selectivity.

Available Once-Daily Formulations

The following NSAIDs can be dosed once daily due to their extended half-lives:

• Meloxicam: 7.5-15 mg once daily (preferential COX-2 inhibitor)
• Nabumetone: 1000-2000 mg once daily
• Piroxicam: 10-20 mg once daily
• Oxaprozin: 600-1200 mg once daily 1
• Celecoxib: 200 mg once daily (selective COX-2 inhibitor)
• Etodolac extended-release: 400-1000 mg once daily

Pharmacologic Rationale

Oxaprozin exemplifies the characteristics needed for once-daily dosing: it has a long elimination half-life, persists in synovial fluid, and reaches peak plasma concentration in 3-6 hours 1. These agents demonstrated equivalent efficacy to traditional NSAIDs like naproxen and aspirin in treating rheumatoid arthritis and osteoarthritis 1.

Clinical Selection Algorithm

For patients ≥75 years old: Strongly prefer topical NSAIDs over oral formulations 2

For patients with GI risk factors:

• History of symptomatic/complicated ulcer (no bleed in past year): Use COX-2 selective inhibitor OR nonselective NSAID + proton pump inhibitor 2
• History of GI bleed within past year: Use COX-2 selective inhibitor + proton pump inhibitor (mandatory combination) 2
• Consider that fixed-dose combinations like ketoprofen/omeprazole ensure compliance with gastroprotection 3

For patients on low-dose aspirin (≤325 mg/day):

• Use nonselective NSAID OTHER than ibuprofen + proton pump inhibitor 2
• Avoid ibuprofen due to pharmacodynamic interaction that reduces aspirin's cardioprotective effect 2
• Do NOT use COX-2 selective inhibitors in this scenario 2

For patients with renal disease:

• Absolute contraindication: Chronic kidney disease stage IV or V (eGFR <30 mL/min) 2
• Use with extreme caution: CKD stage III (eGFR 30-59 mL/min) - individualize based on risk-benefit 2

Critical Precautions

Cardiovascular considerations: All NSAIDs increase mean blood pressure by approximately 5 mm Hg and should be avoided in congestive heart failure 4. Celecoxib may be safer than other COX-2 inhibitors regarding myocardial infarction risk, though all carry some cardiovascular risk 4.

Anticoagulation: Risk of GI bleeding increases 3-6 fold when NSAIDs are combined with anticoagulants, and INR may increase up to 15% 4. Avoid NSAIDs in patients with platelet defects or thrombocytopenia 4.

Pregnancy: Avoid NSAIDs 6-8 weeks before term due to risk of prolonged pregnancy/labor and fetal antiplatelet effects 4.

Hepatic disease: Avoid in cirrhosis due to hematologic and renal complications; particularly avoid sulindac and diclofenac which have higher hepatotoxicity potential 4.

Practical Advantage of Once-Daily Dosing

Once-daily formulations improve adherence to therapy, which is particularly important given that up to 44% of patients are non-adherent to NSAID regimens 3. The fixed-dose ketoprofen/omeprazole combination demonstrates that once-daily formulations can simultaneously ensure both anti-inflammatory therapy and gastroprotection compliance 3.